Handbook of Melatonin-Based Therapy and its Applications
- 1 Edición - 13 de octubre de 2025
- Última edición
- Editores: Alejandro Romero Martínez, Eva Ramos Alonso, Francisco López-Muñoz
- Idioma: Inglés
Handbook of Melatonin-Based Therapy and its Applications provides pharmaceutical researchers and health professionals with a comprehensive reference on the applications of melato… Leer más
Descripción
Descripción
This is a comprehensive resource for pharmaceutical scientists and health professionals involved in developing therapies and applying them to patients. Researchers in the fields of medicine, biology, neuroscience, and pharmacology conducting studies related to melatonin-based will benefit from insights into the latest research findings, clinical trials, and therapeutic approaches.
Puntos claves
Puntos claves
- Covers the most significant clinical aspects where melatonin has been shown to be effective
- Summarizes research progress and therapeutic applications of melatonin
- Provides a platform for researchers from diverse fields to collaborate and advance our understanding of the field
De interès para
De interès para
Índice
Índice
2. Translational melatonin in preclinical models
3. Melatonin and COVID-19
4. Obtaining phytomelatonin and other bio(logical)-melatonin: sources and therapeutic applications
5. Melatonin as a Therapy for Neonatal Encephalopathy: The journey to clinical trials
6. Melatonin Gastroprotection by melatonin: an emerging concept and underlying mechanisms
7. Melatonin as a therapeutic in the skin
8. The use of melatonin in oxidative stress of the newborn
9. Synergistic impact of melatonin on colorectal cancer
10. Melatonin in Oncology: Unveiling its Potential in Prostate Cancer
11. The use of melatonin in pediatric perioperative care
12. Exploring melatonin as a therapeutic approach for mustard vesicants
13. Epigenetic Modulation by Melatonin: Clinical Implications and Therapeutic Prospects
14. Why Melatonin Administration might be harmful during the mounting of a defense response
15. New galenic formulations of melatonin and therapeutic applications
16. Melatonin, sleep and mood disorders
17. Melatonin and neurodegenerative diseases
18. Melatonin and autism spectrum disorders
19. Melatonin and andrology
20. Melatonin and hepatic injury
21. Melatonin treatment against experimental optic Neuritis and glaucoma
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Publicado: 13 de octubre de 2025
- Idioma: Inglés
Sobre los editores
Sobre los editores
AR
Alejandro Romero Martínez
Alejandro Romero Martínez, PhD in Biological Sciences from the University of Vigo (2000), is a Tenured Professor in Toxicology at the University Complutense of Madrid. His research activity has resulted in 105 Journal Citation Reports (JCR) articles (h-index 38). He is also the coauthor of 12 international book chapters and 4 national. Moreover, he coauthors >50 international and >40 national congress communications and 2 patents. He has supervised two doctoral theses. He is a member of 4 editorial committees and has acted as reviewer/evaluator of 72 international journals in his specialty with JCR relative quality index. He combines his interest and background on molecular toxicology and neuroprotection studies of new molecules with therapeutic interest against neurodegeneration and focuses on novel melatonin-based therapies. He has made important contributions in cell/molecular biology of new multitarget compounds synthesized against key targets in Alzheimer’s disease and advances in the knowledge of melatonin as a pleiotropic agent against several pathologies and mechanisms of toxicity. Dr. Martinez led the MELVES project (medical countermeasures program SYP41804) to test melatonin as a potential health support measure for treatment and prophylaxis. Remarkably, the Spanish Ministry of Defence-General Directorate of Armament and Material/SDG PLATIN has displayed interest by selecting his project. He has collaborated as an external reviewer for the Czech Science Foundation and Medical Research Council’s Developmental Pathway Funding Scheme (DPFS). Moreover, he is a member of the Spanish Association of Toxicology (AETOX) since January 2011, and certified as a European Registered Toxicologist (ERT).
EA
Eva Ramos Alonso
FL
Francisco López-Muñoz
Dr. Francisco López-Muñoz is PhD degree in Medicine (Complutense University of Madrid) and specialist in Pharmaceutical Medicine. Currently, he is a Full Professor of Pharmacology, Vice-Chancellor of Research and Science, Chairman of the Research Ethics Committee at Camilo José Cela University (Madrid), and a research fellow at “Hospital 12 de Octubre” Research Institute (Madrid, Spain). He is editor/author of 32 books and author of 800 scientific articles and chapters related to psychopharmacology, 197 of them with JCR impact factor (h-index 47).